Novo Nordisk Juggles Cyber Incident and Pipeline Data as Shares Struggle to Recover

Novo Nordisk shares fall as cyberattack exposes patient data, but Phase 2 results for Zenagamtide show 14.6% weight loss and strong HbA1c reduction, highlighting long-term pipeline potential.

Novo Nordisk is navigating a complex landscape where breakthrough clinical data and a serious security breach coexist, leaving investors to weigh near-term risks against a promising long-term pipeline. The Danish drugmaker’s shares have lost nearly half their value from a 52-week high of €70.13, and even the unveiling of impressive trial results for its next-generation candidate Zenagamtide has done little to shift the prevailing bearish sentiment.

Cyber Attack Exposes Patient Data

On June 11, the company confirmed that an unauthorised party had gained access to sensitive patient information from clinical trials. The stolen data included patient IDs, birth years and health records, though the company stated that no names were compromised, making direct identification of participants unlikely without additional context. Novo Nordisk immediately took affected IT systems offline and enlisted external cybersecurity specialists to investigate the breach.

The incident carries significant regulatory implications. The company is required to report the data theft to the relevant European privacy authorities, and market observers expect formal inquiries to follow. Potential consequences range from hefty fines to stricter compliance mandates for the group’s IT infrastructure. Management has so far declined to disclose the identity of the attackers or the full scope of the data exfiltration, leaving a cloud of uncertainty over the shares.

Zenagamtide Data Stands Out

Against this security backdrop, Novo Nordisk presented standout results from a Phase 2 trial of Zenagamtide — also known as Amycretin — at the ADA congress in New Orleans. The drug is a first-in-class molecule that simultaneously activates GLP-1 and amylin receptors, setting it apart mechanically from all approved GLP-1 agonists including Semaglutide.

The trial enrolled 262 adults with type 2 diabetes and tested six subcutaneous doses against placebo over 36 weeks. At the highest dose of 40 mg, patients achieved a mean weight loss of 14.6%, compared with just 2.1% in the placebo arm. HbA1c levels fell by up to 1.71 percentage points from a baseline of 7.8%, and nearly 89% of participants in that group reached an HbA1c below 7%. Importantly, weight loss had not plateaued at higher doses by week 36, suggesting further potential with extended treatment.

Novo Nordisk plans to launch the Phase 3 programme for Zenagamtide in type 2 diabetes during the second half of 2026, with initial readouts not expected before 2028. The company also presented Phase 3 data from the REIMAGINE programme for CagriSema, a weekly combination of an amylin analogue and a GLP-1 agonist, showing consistent reductions in HbA1c and body weight.

Oral Wegovy Gains Traction

On the commercial front, the oral version of Wegovy at a 25 mg dose has surpassed 3 million prescriptions in the United States in just over five months. International rollouts are set to begin in the second half of 2026, starting with the already approved launch in the United Arab Emirates. This pill-based formulation is seen as a key driver for expanding the addressable market beyond injectable therapies.

Stock Under Siege

Despite these positives, the equity continues to trade under pressure. At €38.40, the shares are up barely 1% on the day following the Zenagamtide announcement, but down roughly 14% year-to-date. In Danish kroner, the stock has slipped to around 281, a year-to-date decline of nearly 15%. The broader sell-off reflects structural headwinds: intensifying competition in the GLP-1 space, U.S. drug pricing policy pressures, and two consecutive profit warnings.

The company’s own forward guidance points to falling sales and earnings for the current year. From January 1, 2027, Novo Nordisk is scheduled to cut U.S. list prices on key Semaglutide brands — a pre-emptive move that will further weigh on revenue. The data theft now adds a compliance risk to an already stretched operational outlook.

Buyback Programme Continues

A share repurchase plan remains in motion. By early February 2027, Novo Nordisk intends to buy back B-shares worth up to 11.2 billion Danish kroner. Since the programme began in February 2026, nearly 5 billion kroner have already been deployed. The buyback signals management’s confidence in the long-term value of the pipeline, but for now, the stock remains hostage to a convergence of external threats and internal challenges.